MedRx Past Earnings Performance
Past criteria checks 0/6
MedRx has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been declining at an average rate of 4.3% per year.
Key information
13.4%
Earnings growth rate
37.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | -4.3% |
| Return on equity | -22.2% |
| Net Margin | -227.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How MedRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 255 | -581 | 158 | 737 |
| 30 Jun 24 | 254 | -512 | 105 | 737 |
| 31 Mar 24 | 23 | -770 | 98 | 737 |
| 31 Dec 23 | 29 | -932 | 221 | 737 |
| 30 Sep 23 | 79 | -1,147 | 301 | 921 |
| 30 Jun 23 | 56 | -1,211 | 334 | 921 |
| 31 Mar 23 | 64 | -1,205 | 341 | 921 |
| 31 Dec 22 | 59 | -1,111 | 234 | 921 |
| 30 Sep 22 | 9 | -1,017 | 219 | 794 |
| 30 Jun 22 | 10 | -967 | 176 | 794 |
| 31 Mar 22 | 2 | -993 | 195 | 794 |
| 31 Dec 21 | 8 | -1,059 | 270 | 794 |
| 30 Sep 21 | 108 | -810 | -51 | 967 |
| 30 Jun 21 | 107 | -874 | -3 | 967 |
| 31 Mar 21 | 122 | -1,074 | 199 | 967 |
| 31 Dec 20 | 115 | -1,114 | 237 | 967 |
| 30 Sep 20 | 16 | -1,401 | -125 | 1,512 |
| 30 Jun 20 | 156 | -1,462 | 93 | 1,512 |
| 31 Mar 20 | 151 | -1,451 | 88 | 1,512 |
| 31 Dec 19 | 169 | -1,616 | 278 | 1,512 |
| 30 Sep 19 | 168 | -1,523 | 715 | 980 |
| 30 Jun 19 | 28 | -1,562 | 617 | 980 |
| 31 Mar 19 | 26 | -1,442 | 493 | 980 |
| 31 Dec 18 | 8 | -1,267 | 296 | 980 |
| 30 Sep 18 | 187 | -1,112 | 408 | 888 |
| 30 Jun 18 | 188 | -979 | 336 | 888 |
| 31 Mar 18 | 180 | -984 | 355 | 888 |
| 31 Dec 17 | 198 | -884 | 283 | 888 |
| 30 Sep 17 | 19 | -975 | 43 | 1,074 |
| 30 Jun 17 | 30 | -1,029 | 58 | 1,074 |
| 31 Mar 17 | 31 | -1,215 | 230 | 1,074 |
| 31 Dec 16 | 22 | -1,259 | 280 | 1,074 |
| 30 Sep 16 | 24 | -1,343 | 688 | 716 |
| 30 Jun 16 | 32 | -1,249 | 600 | 716 |
| 31 Mar 16 | 32 | -980 | 330 | 716 |
| 31 Dec 15 | 37 | -878 | 306 | 716 |
| 30 Sep 15 | 36 | -734 | 162 | 718 |
| 30 Jun 15 | 20 | -772 | 166 | 718 |
| 31 Mar 15 | 38 | -841 | 247 | 718 |
| 31 Dec 14 | 26 | -1,016 | 299 | 718 |
| 30 Sep 14 | 45 | -1,006 | 638 | 397 |
| 30 Jun 14 | 43 | -956 | 570 | 397 |
| 31 Mar 14 | 52 | -793 | 431 | 397 |
| 31 Dec 13 | 68 | -621 | 263 | 397 |
Quality Earnings: 4586 is currently unprofitable.
Growing Profit Margin: 4586 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4586 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare 4586's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4586 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: 4586 has a negative Return on Equity (-22.16%), as it is currently unprofitable.